Find guidance on which studies require registration on ClinicalTrials.gov (http://clinicaltrials.gov/), who is responsible and how to register through the University of Pittsburgh.
Who is Responsible?
The initiator/sponsor (responsible for overall study preparation, planning and control; when applicable, the FDA IND/IDE holder) should coordinate with collaborators but is ultimately responsible for registration.
When to Register?
- Intent on Journal Publication: Register (verify NCT number assigned and posted on public site) prior to informed consent of the first participant.
If informed consent of first participant occurred prior to July 1, 2005, register prior to journal submission.
- NO Intent on Journal Publication: Submit to ClinicalTrials.gov no later than 21 calendar days following the Study Start Date (as defined above).
Understanding the Study Start Date: Study Start (Initiation) Date is the date on which the first participant is enrolled. "Enrolled" means a participant's, or their legally authorized representative’s, agreement to participate in a clinical study following completion of the informed consent process. Potential participants who are screened for the purpose of determining eligibility for the study, but do not participate in the study, are not considered enrolled, unless otherwise specified by the protocol.
Which Studies Require Registration?
- FDA-Regulated Applicable Clinical Trials
Applicable Clinical Trials (ACTs) include Phase 2-4 drug trials; most device trials; FDA-ordered pediatric postmarket device surveillance
The Food and Drug Administration Amendments Act of 2007, Section 801 (FDAAA 801) (studies initiated prior to January 18, 2017) and the regulations implementing FDAAA 801 (studies initiated on or after January 18, 2017) require registration of Applicable Clinical Trials (ACTs) of drugs and medical devices initiated after September 27, 2007, and those initiated previously and ongoing as of December 26, 2007.- Exercise caution in determining whether the study evaluates at least one drug, biological, or device product regulated by the U.S. FDA. This is not the same as determining whether the study is conducted under an IND application or IDE. Refer to the "Oversight" guidance in the Tip Sheet (link above).
- Studies that evaluate health outcomes (i.e., preliminary safety and effectiveness) in addition to device feasibility or include at least 10 subjects are generally not considered Device Feasibility studies in the context of ACT determination.
- NIH-Funded Clinical Trials
All NIH-funded clinical trials (not limited to drug and device interventions)
The NIH Policy on the Dissemination of NIH-Funded Clinical Trial Information requires registration of any NIH-funded clinical trial initiated on or after January 18, 2017, for which support for conduct of the trial is requested in an application for funding (including for grants, other transactions and contracts) submitted on or after January 18, 2017.- Refer to the PHS Human Subjects and Clinical Trials Information Form in the grant application and the specific Notice of Award for more information.
Important points on NIH-defined Basic Experimental Studies with Humans (BESH)
NIH considers BESH proposed in funding applications with due dates on or before May 24, 2026 to be clinical trials subject to the Policy. Refer to the Basic Experimental Study Involving Humans (BESH) Legacy Information.- There is flexibility for BESH submitted to funding opportunities designated as “basic experimental studies with humans” in the title (NOT “clinical trial required” or “clinical trial optional” funding opportunities) to register and report results on alternative publicly available platforms, if so described in the funding application. However, the study may still need to be registered on ClinicalTrials.gov per ICMJE Policy (see below).
NIH does NOT consider BESH proposed in funding applications with due dates on or after May 25, 2026 to be clinical trials subject to the Policy. Refer to Is My Project a Clinical Trial, Basic Experimental Study Involving Humans (BESH), or an Observational Study Involving Humans?
- However, the study may still need to be registered on ClinicalTrials.gov per ICMJE Policy (see below).
View the presentation on NIH Changes for BESH for more information.
- Studies Intended on Journal Publication
ICMJE-defined clinical trials where there is intent on publishing the results in a journal
The International Committee of Medical Journal Editors (ICMJE) Clinical Trial Registration Policy requires registration of ICMJE-defined clinical trials (not limited to drug and device interventions) at or before the time of first patient consent for enrollment as a condition of consideration for publication. If first patient consent for enrollment was prior to July 1, 2005, registration is required prior to journal submission.- The ICMJE has a broader definition of clinical trial than NIH, which may include NIH-defined Basic Experimental Studies with Humans (see above).
- Some journals may have their own study registration policies that are broader in scope (e.g., including observational studies). Inquire with your journals of interest before initiating your study.
- There are special considerations when studying an FDA-regulated device product that is not yet approved or cleared. Refer to the "Oversight" guidance in the Tip Sheet (link above).
- Studies Billing Health Insurance
Refer to the Centers for Medicare and Medicaid Services (CMS) Change Request 8401.
- Other Funder or Collaborator Requirements
Review applicable grants and/or contracts for other funding agency or collaborator requirements.
Where to Register?
The ClinicalTrials.gov PRS account of the Sponsor Organization – primary organizational affiliation of the initiator (responsible for overall preparation, planning and control) of the study. When applicable, the FDA IND or IDE holder is the initiator.
- The University of Pittsburgh (UPittsburgh) PRS account is used when University of Pittsburgh or UPMC is the Sponsor Organization.
How to Register?
The Responsible Party (Sponsor-Investigator or IRB-approved Principal Investigator) and any team members assisting will need UPittsburgh PRS user accounts to register the study. Send the request including full names, preferred business e-mail addresses, and the PittPRO STUDY number (if applicable) to CTgov@pitt.edu. Refer to the SOP linked at the top of this page for further information.